Short answer
Bristol Myers Squibb (BMY) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $12.2B (up 2.8% year over year) with net income of $2.2B.
Q3 2025 key financials · XBRL
- Revenue
- $12.2B
- +2.8% YoY · −0.4% QoQ
- Net income
- $2.2B
- +81.8% YoY · +68.0% QoQ
- EPS (diluted)
- $1.08
- +80.0% YoY · +66.2% QoQ
Source: XBRL data from the Bristol Myers Squibb (BMY) Q3 2025 10-Q on SEC EDGAR. USD.
Bristol Myers Squibb Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue details not explicitly provided in excerpt; focus on expense trends instead
- Operating expenses $9.11B Q3 2025 vs $10.22B Q3 2024, down 11% YoY; YTD $27.83B vs $44.51B, down 37% YoY
- Cost of products sold $3.44B Q3 2025, up 16% YoY; driven by alliance profit sharing and product mix
- SG&A $1.79B Q3 2025, down 10% YoY due to strategic cost savings; R&D $2.53B Q3, up 6% YoY driven by IPRD impairment
- Acquired IPRD charges spiked to $633M Q3 2025 from $262M prior year; amortization $831M Q3, down 65% YoY due to Revlimid fully amortized
- Other income/(expense) net $(108)M Q3 2025 vs $234M expense prior year; includes interest expense $480M Q3, slightly down YoY
- No direct segment revenue information; largest expense driver noted is product sales and alliance sharing
- Management notes ongoing strategic productivity initiatives cutting SG&A and R&D costs this year
- No revised guidance or explicit near-term outlook commentary included in this section
Risk Factors
- No newly added risk factors explicitly stated this quarter, focus on product approvals updates
- Regulatory risk from accelerated approvals of Opdivo + Yervoy for multiple indications in Japan, EC, and FDA between Feb-Aug 2025
- Market risk from increased competition in immuno-oncology given multiple new first-line treatment approvals of Opdivo + Yervoy
- Operational risk related to integration of expanded portfolio from recent approvals including Camzyos and Breyanzi in Japan and EC
- Financial risk due to potential revenue concentration on Opdivo + Yervoy with multiple approvals enhancing dependency on these products
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bristol Myers Squibb quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.